These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 31427060)

  • 1. Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management.
    De Cock D; Hyrich K
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):869-886. PubMed ID: 31427060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
    Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
    BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.
    Kang EH; Liao KP; Kim SC
    Curr Rheumatol Rep; 2018 May; 20(7):42. PubMed ID: 29846814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Rheumatoid Arthritis: An Overview.
    Radu AF; Bungau SG
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
    Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
    Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis.
    Simon TA; Thompson A; Gandhi KK; Hochberg MC; Suissa S
    Arthritis Res Ther; 2015 Aug; 17(1):212. PubMed ID: 26271620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Cho SK; Lee J; Han M; Bae SC; Sung YK
    Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics in rheumatoid arthritis.
    Sen D; Paul JR; Ranganathan P
    Methods Mol Biol; 2014; 1175():625-60. PubMed ID: 25150878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.
    Goodman SM
    Drugs Aging; 2015 May; 32(5):361-9. PubMed ID: 25941102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis.
    Lin YJ; Anzaghe M; Schülke S
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
    Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. South African recommendations for the management of rheumatoid arthritis: an algorithm for the standard of care in 2013.
    Hodkinson B; Van Duuren E; Pettipher C; Kalla A;
    S Afr Med J; 2013 Jun; 103(8 Pt 2):576-85. PubMed ID: 23885741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
    Raaschou P; Simard JF; Neovius M; Askling J;
    Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC
    BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Biological Activities of Chemical Drugs for the Treatment of Rheumatoid Arthritis.
    Zhou S; Zou H; Chen G; Huang G
    Top Curr Chem (Cham); 2019 Sep; 377(5):28. PubMed ID: 31563994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.
    García-Hernández MH; González-Amaro R; Portales-Pérez DP
    Immunotherapy; 2014; 6(5):623-36. PubMed ID: 24896630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal Manifestations of Rheumatoid Arthritis.
    Kapoor T; Bathon J
    Rheum Dis Clin North Am; 2018 Nov; 44(4):571-584. PubMed ID: 30274624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.